PROGRESS UPDATE. A Kids Brain Tumor Cure Foundation
|
|
- Ella Newton
- 5 years ago
- Views:
Transcription
1 PROGRESS UPDATE A Kids Brain Tumor Cure Foundation September 2016
2 EXECUTIVE SUMMARY Primary cancers of the brain have surpassed leukemias to become the number one cause of cancer-related death in children. Pediatric low-grade astrocytomas (PLGAs) are the most common brain tumor of childhood. The current standard of care for PLGA patients is surgery, chemotherapy, and radiation, all carrying long-lasting, adverse side effects. Therefore, there is an urgent need for a new therapeutic approach, smart drugs, that specifically target the underlying molecular causes of cancer with minimal collateral damage. The Pediatric Low-Grade Astrocytoma Program at Dana-Farber is a group of internationally renowned experts devoted to advancing targeted therapy treatments for this devastating disease. Under the leadership of Mark Kieran, MD, PhD, Director of Pediatric Neuro-Oncology, and Charles Stiles, PhD, the group is spearheading basic science investigations that are revealing key biologic and molecular information, the foundation for developing new targeted therapies in current and planned clinical trials. Mark Kieran, MD, PhD, Director, Pediatric Neuro- Oncology Please continue to read to learn about the groundbreaking findings that offer hope in fighting this horrible childhood cancer. As we advance discoveries and care, we are grateful for your partnership in supporting this important work, which will impact patients and their families for many years to come. IDENTIFYING THE MOLECULAR DAMAGE IS THE KEY TO THE CURE Smart drugs for the most common oncogenic mutation in PLGA Approximately 70 percent of PLGA tumors have mutations in a gene known as BRAF, which encodes an enzyme critical to the control of cell growth and division. There are two common forms of mutant BRAF found in PLGAs. One form (known as BRAFV600E ) is found also in malignant melanoma a deadly and very common skin tumor of adults. It is fortuitous that a drug, dabrafenib, is already approved to treat adult BRAF tumors. Taking advantage of this opportunity, Dr. Kieran is leading an international clinical trial of dabrafenib for pediatric patients with advanced tumors that have BRAFV600E. After a phase I trial resulted in a promising response rate, Dr. Charles Stiles, PhD 2
3 Kieran and his colleagues launched the phase II trial to further test dabrafenib across several additional types of pediatric cancer. Dr. Kieran presented these encouraging early results at the June 2015 American Society of Clinical Oncology meeting. Unfortunately the most common BRAF mutation in PLGAs is not BRAFV600E but rather a mutation known as KIAA1549BRAF. This mutation is resistant to dabrafenib and other drugs approved for the BRAFV600E mutations found in adult melanomas. Dr. Stiles and PLGA Program investigators Nathalie Agar, PhD, Sara Buhrlage, PhD, and Rosalind Segal, MD/PhD have identified a promising new drug, TAK580, which can target both types of BRAF mutation. Dr. Kieran will be taking TAK580 forward into clinical trials that will hopefully begin enrolling patients by December of this year. In a third avenue, Dr. Stiles and his collaborators discovered that the BRAF fusion mutation may lead to abnormal activity in a downstream gene called MEK, causing uncontrolled cellular growth. Dr. Stiles and his team are exploring whether targeting MEK can indirectly block abnormal BRAF activity. Toward this goal, Dr. Kieran launched a multi-center clinical trial in 2015 to test the drug MEK162 in patients with the BRAF fusion gene. Accounting for the other 30 percent of PLGAs: MYB-QKI Thirty percent of PLGA tumors do not contain a BRAF mutation. Using data collected during genomic studies at Dana-Farber and other cancer centers, Rameen Beroukhim, MD, PhD, Pratiti Bandopadhayay, MD, PhD, and Keith Ligon, MD, PhD, recently identified an alteration in angiocentric gliomas, a rare form of low-grade glioma for which the causes were previously unknown. The team specifically identified the MYB-QKI fusion mutation an abnormality that occurs when two genes fuse together as an important driver of this disease. Through further preclinical studies, they determined that this fusion mutation promoted tumor growth through three distinct mechanisms, representing the first known example of three impacts derived from a single mutational change. This discovery was published in the March 2016 issue of Nature Genetics. Since this recently identified tumor type is challenging to diagnose, the disease is often misidentified and over-treated with extra chemotherapy or radiation, which can have negative long-term impacts. The MYB-QKI fusion Rameen Beroukhim, MD, PhD Pratiti Bandopadhayay, MD, PhD Keith Ligon, MD, PhD, Director, Neuro-Oncologic Pathology 3
4 mutation is unique to angiocentric gliomas, and could thereby help investigators to better diagnose and treat the disease effectively while reducing side effects. The team is conducting additional studies in cell lines and mouse models to learn more about how best to block this mechanism with therapy. Homing in on p53 and Olig2 As one of the most commonly altered genes linked to cancer, p53 remains an important therapeutic target in PLGA. In addition, Dr. Stiles and his colleagues learned that a protein called Olig2 is expressed in cells that give rise to PLGAs. While previous efforts to block the cancer-driving activities of these genes have not yet proven to be successful, Dr. Stiles and his team are exploring novel strategies to block these altered genes. Through their work in laboratory models, they aim to learn more about how inhibiting these targets impacts PLGA to clarify how these genes function and to develop better strategies to target them with therapy. The road ahead: Bolstering PLGA research through sample collection and mouse models To learn more about the key drivers of pediatric gliomas, Dana-Farber investigators continue to develop their bank of tumor samples from patients at Dana-Farber and PLGA consortium sites. All patients with PLGA at Dana- Farber have the opportunity to contribute samples, helping to build a longterm research tool that investigators can use to conduct genomic sequencing and pre-clinical research aimed to further elucidating the biology underlying these tumors (see Profile sidebar). With a consent rate of more than 90 percent, the pediatric glioma tumor bank now has more than 350 samples available to bolster research efforts. As part of this project, the team is developing mouse models of PLGA that recapitulate key characteristics of patient tumors. Using these models, the team is continuing to identify other alterations linked to PLGA and collaborating with Dana-Farber s chemical biologists to explore strategies for targeting these activities. These multifaceted studies are uniting Dana-Farber s finest leaders to accelerate drug discovery and development. 4
5 Since its inception, the PLGA Program has initiated several landmark projects, including the tissue bank. This pie chart depicts the breakdown of pediatric glioma subtypes identified through the tissue bank, with low-grade astrocytomas as the most common form of childhood brain cancer. Image on left courtesy of Dr. Stiles NEURO-ONCOLOGY OUTCOMES AND SURVIVORSHIP Today, there are more than 350,000 survivors of pediatric cancers in the United States. This progress can be attributed to many key advances in the field, allowing for improved treatments to help young patients. With this increase in the number of survivors, investigators can now explore ways to fine-tune treatment plans that will maximize efficacy while minimizing the potential late effects of therapy. As discovery science reveals more about the specific drivers of childhood brain tumors, investigators are increasingly able to personalize treatment and deliver therapies that are maximally effective while also considering the longterm health of young patients. Peter Manley, MD, Director of the Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic, and his team aim to better understand and reduce treatment side effects, ensuring that patients with pediatric brain tumors receive optimal care and that survivors experience ongoing support. The Stop & Shop Family Pediatric Neuro- Oncology Outcomes Clinic provides patients and their families with the resources and assistance that they need to navigate a pediatric brain tumor diagnosis, treatment, and survivorship. Peter Manley, MD, Director, Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic 5
6 THE POWER OF PHILANTHROPY Thank you for your commitment, which helps Dana-Farber investigators to lead pioneering projects that advance our understanding of pediatric lowgrade astrocytoma. These discoveries strengthen our ability to uncover and deliver new therapeutic options for patients, keeping Dana-Farber at the forefront of pediatric cancer research and care. On behalf of our patients and their families, thank you for your generous support in these critical efforts. Report written by Brittany Flaherty. FOR MORE INFORMATION Amy Trapasso Director, Corporate and Foundation Relations Telephone: (617) Dana-Farber Cancer Institute. All Rights Reserved. No part of this report may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by an information storage or retrieval system, without permission in writing from Dana-Farber Cancer Institute. For additional information, please contact Jane Anderson at or % of all designated gifts will support our Faculty Research Fund to advance Dana-Farber s research mission. 6
PROGRESS UPDATE. Lauren s First and Goal
PROGRESS UPDATE Lauren s First and Goal August 2015 EXECUTIVE SUMMARY The Pediatric Low-Grade Astrocytoma (PLGA) Program at Dana-Farber Cancer Institute is committed to improving outcomes for young patients
More informationPROGRESS UPDATE. The Prayers From Maria Foundation
PROGRESS UPDATE The Prayers From Maria Foundation August 2016 EXECUTIVE SUMMARY Dana-Farber Cancer Institute is a global leader in discovery science and patient care for pediatric brain tumors, including
More informationPROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund
PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund October 2017 EXECUTIVE SUMMARY Investigators at Dana-Farber Cancer Institute are global leaders in pediatric brain tumor research and patient care,
More informationA report on the Pediatric Low-Grade Astrocytoma (PLGA) Program Prepared for the Lauren s First and Goal Foundation August 6, 2013
A report on the Pediatric Low-Grade Astrocytoma (PLGA) Program Prepared for the Lauren s First and Goal Foundation August 6, 2013 EXECUTIVE SUMMARY Over the past several years, the Pediatric Low Grade
More informationPROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund
PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund December 2018 EXECUTIVE SUMMARY As a top-ranked pediatric cancer center, Dana-Farber Cancer Institute combines first-rate patient care with groundbreaking
More informationPROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund
PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund January 2015 EXECUTIVE SUMMARY Since its founding in 1947, Dana-Farber Cancer Institute has been dedicated to advancing pediatric cancer research and
More informationPROGRESS UPDATE. The Pan-Mass Challenge
PROGRESS UPDATE The Pan-Mass Challenge Fall 2017 PAN-MASS CHALLENGE: HITTING A HIGHER GEAR IN THE FIGHT AGAINST CANCER For nearly four decades, the Pan-Mass Challenge (PMC) and Dana- Farber Cancer Institute
More informationAn update on your support of the Kaplan Cancer Research Fund Swedish Cancer Institute
An update on your support of the Swedish Cancer Institute At Swedish, we re committed to offering our patients the newest, most innovative cancer treatment available. Through your support of the at the
More informationThomas C. Wilmot, Sr. Judy Wilmot Linehan
Thomas C. Wilmot, Sr. Judy Wilmot Linehan The Wilmot Family For more than 35 years, the Wilmot family has been dedicated to supporting cancer research and care for the Rochester community. Their generosity
More informationStewardship Report. Presented to. The Harold E. Eisenberg Foundation
Stewardship Report Presented to The Harold E. Eisenberg Foundation June 2018 Our Appreciation Dear Harold E. Eisenberg Foundation Board Members and Friends, On behalf of the Robert H. Lurie Comprehensive
More informationBRANCHED-CHAIN AMINO ACIDS FOUND TO REGULATE THE DEVELOPMENT AND PROGRESSION OF CANCER
SCIENTIFIC ADVISORY BRANCHED-CHAIN AMINO ACIDS FOUND TO REGULATE THE DEVELOPMENT AND PROGRESSION OF CANCER Researchers from A*STAR s SBIC have discovered how changes in BCAA metabolism influence the development
More informationClaudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS
Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS Brain Cancer New Treatment Opportunities - Discovery of new pathways in brain cancers
More informationNeurofibromatosis (NF) Center
Washington University Neurofibromatosis (NF) Center THE NF CENTER: EXCEPTIONAL CARE THROUGH GROUNDBREAKING RESEARCH An international leader in research and treatment of neurofibromatosis (NF), the Washington
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationOutstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014
Outstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014 Answers provided as a courtesy by Dana Farber Cancer Institute experts: Dr. Mark Kieran Dr. Peter Manley
More informationSeptember is Childhood Cancer Awareness Month. Advocacy Toolkit. cancer.chop.edu/cancerawareness
September is Childhood Cancer Awareness Month. Advocacy Toolkit cancer.chop.edu/cancerawareness September is Childhood Cancer Awareness Month. Make your voice heard. Dear Friend, At The Children s Hospital
More informationThe Lung Cancer Network: Collaborate to Cure
The Lung Cancer Network: Collaborate to Cure The Gala Wednesday, June 6, 2018 Opportunities for Support Everything You Need to Know About the 2018 Gala World-class collaboration. Join us on June 6, 2018
More informationLEADERSHIP PROFILE. CURE Childhood Cancer believes that childhood cancer can be cured in our lifetime. -- CURE Childhood Cancer s Vision
LEADERSHIP PROFILE CURE Childhood Cancer Atlanta, Georgia CURE Childhood Cancer believes that childhood cancer can be cured in our lifetime. -- CURE Childhood Cancer s Vision THE OPPORTUNITY This is a
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_mutation_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationPLEASE INVEST IN PROJECT IMPACT TO SAVE THESE KIDS
PLEASE INVEST IN PROJECT IMPACT TO SAVE THESE KIDS MORE THAN 4,600 AMERICAN CHILDREN HEAR THE WORDS BRAIN TUMOR UTTERED BY THEIR DOCTORS EVERY YEAR. FOR THOSE PATIENTS AND THEIR FAMILIES, THE IMPACT OF
More informationDONOR RECOGNITION PROGRAM
DONOR RECOGNITION PROGRAM HARLEY S ANGELS CRUIZIN TO CURE Mission Statement The Mission of Harley's Angels is to promote breast cancer awareness, education, and support of research for the prevention and
More informationSustain and Seize Cancer Research Opportunities
One Voice Against Cancer (OVAC) appreciates the opportunity to submit written comments for the record regarding funding for cancer programs for research, prevention, detection, and treatment as well as
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationYale Center For Clinical Investigation. Internship Program. Join Our Growing Team and Help Us Discover. Yale
Center For Clinical Investigation Internship Program Join Our Growing Team and Help Us Discover Moving Science Forward Local teens take the artificial pancreas for a test run at City Climb Gym in New Haven.
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationMedia Kit: Pediatric Brain Tumor Foundation. Catherine Whitlock. Purdue University
Media Kit: Pediatric Brain Tumor Foundation Catherine Whitlock Purdue University Pediatric Brain Tumor Foundation Announces Fall Signature Events ASHEVILLE, N.C., Sept. 1, 2016 Today the Pediatric Brain
More informationFast-Forwarding a Cure for Melanoma
Fast-Forwarding a Cure for Melanoma Vision Targeting an Urgent Problem Melanoma often starts out small, misleadingly insignificant a change in a mole, a mark on a fingernail. But the consequences can be
More informationPediatric Brain Tumor Research
Research into two rare and aggressive childhood brain tumors unveils discoveries that may be applicable well beyond those pediatric cancers. recent and ongoing research has led to important discoveries
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More information2017FACTs. Discover. Care. Believe.
2017FACTs Discover. Care. Believe. Who We Are Founded in Boston in 1947, Dana-Farber Cancer Institute is world-renowned for its leadership in adult and pediatric cancer treatment and research. A principal
More informationPROGRESS UPDATE. The Pan-Mass Challenge
PROGRESS UPDATE The Pan-Mass Challenge Fall 2014 2014: THE 35 TH PAN-MASS CHALLENGE The Pan-Mass Challenge (PMC), founded in 1980 by Executive Director Billy Starr, who was made a Dana- Farber Cancer Institute
More informationChildren s Research Institute
Children s Research Institute Children s National Health System Learning that a child has a serious health condition is devastating. Yet, no matter how dire a diagnosis may be, parents hold out hope that
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationCancer changes lives, but so do you. How YOU are changing the cancer story
Cancer changes lives, but so do you. How YOU are changing the cancer story Research and Clinical Trials Report to Donors 2017 You ve given the gift of HOPE Hope is at the heart of cancer research. Hope
More informationStrategic Direction. At The Kids Cancer Project our vision is to find a cure for kids cancer
2016-2018 Strategic Direction At The Kids Cancer Project our vision is to find a cure for kids cancer Our commitment Through the power of science, The Kids Cancer Project is at the forefront fighting for
More informationI. CHESTER COUNTY COMMUNITY FOUNDATION GRANT PROPOSAL SUMMARY SHEET Date September 20, 2018
Contact Information Organization Name: AACR Foundation established to support the American Association for Cancer Research (AACR) Address: 615 Chestnut Street 17 th Floor Philadelphia, PA 19106 Phone:
More informationOverview. Professional education to help multidisciplinary childhood cancer professionals to stay up-to-date in this rapidly changing field.
Overview What is the Get Up and Go for POGO! fundraising program? It is an employee giving program that promotes community service by raising funds to support the work of the Pediatric Oncology Group of
More informationTHE D10 CHICAGO. The Difference We re Making
THE D10 CHICAGO The Difference We re Making The Difference the D10 Made for Shree Shree is a 24-year-old with Down syndrome and relapsed leukemia. Completing her treatment with Rush in 2006, she was cancer-free
More informationAccelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationThe Impact of Ben s Run
December 2017 The Impact of Ben s Run AT CHILDREN S NATIONAL HOSPITAL For nearly 150 years, Children s National has been committed to providing exceptional, compassionate care to every child, no matter
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationMassachusetts General Hospital Cancer Center Thematic Priorities 2012 Allocation Report
Massachusetts General Hospital Cancer Center Thematic Priorities 2012 Allocation Report Providing the finest, personalized care to every patient is central to the Massachusetts General Hospital Cancer
More informationCenter for Cell Therapy and Regenerative Medicine (CCRG)
Center for Cell Therapy and Regenerative Medicine (CCRG) What is CCRG? CCRG is a multidisciplinary platform for new types of cellular therapy and tissue therapy. It is located on the campus of the Antwerp
More informationA World Free From Cancer. BC Cancer Foundation 2011 Report to Donors
A World Free From Cancer BC Cancer Foundation 2011 Report to Donors For the year ended March 31, 2011 Table of Contents Page 3 Page 5 Partners in Discovery A Message from the BC Cancer Foundation Chairman
More informationDriving Progress in Pediatric Cancer Research
Driving Progress in Pediatric Cancer Research A report for the Ted Mullin Fund March 2017 2 Thank you to the Ted Mullin Fund and its donors for their leadership in driving pediatric cancer research, care,
More informationFighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program
Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program Joxel Garcia, MD, MBA Executive Director, Cancer Prevention and Control Platform Member, Moon Shots Program Leadership Team The
More informationGIFT. For more information call 1-(833) or
For more information call 1-(833) 879-5983 or email postmortemdonation@cbttc.org GIFT The gift of a post-mortem tissue donation benefits other children diagnosed with a pediatric brain tumor and can provide
More informationMr. Kevin Dwan. The Sabrina Foundation Center for Cardiovascular Health in Pregnancy
A Proposal to Mr. Kevin Dwan For support of The Sabrina Foundation Center for Cardiovascular Health in Pregnancy A Proposal for the Support of The Sabrina Foundation Center for Cardiovascular Health in
More informationParkinson s Research and the New Centre for Brain Health at UBC. Case for Support The University of British Columbia Faculty of Medicine
Parkinson s Research and the New Centre for Brain Health at UBC Case for Support The University of British Columbia Faculty of Medicine THE VALUE OF A HEALTHY BRAIN By 2020, brain disease will overtake
More informationRSRT Awards $10 Million to Preeminent Researchers in Pursuit of Curing Devastating Neurological Disorder
P R E S S R E L E A S E RSRT Awards $10 Million to Preeminent Researchers in Pursuit of Curing Devastating Neurological Disorder September 25, 2018 Media Contacts: Monica Coenraads Executive Director,
More informationPRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER
PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER This collaboration creates the world s first clinically reliable and
More informationfinding cures for all cancers
finding cures for all cancers investing in our research cruk.org Finding cures for all cancers. Investing in Our Research Welcome On behalf of Cancer Research UK, I would personally like to thank you for
More informationTeam Captain Tool Kit
Greensboro LUNGe Forward 5K & 1K Benefiting the Lung Cancer Initiative of North Carolina Saturday, November 8, 2014 Team Captain Tool Kit Lung Cancer Initiative of N.C. 4000 Blue Ridge Road, Suite 170
More informationWith your help, our goal is to protect millions more against serious illness through the development of new vaccines and other preventions.
Millions of children are alive, healthy, and have grown to productive adulthood because of what our scientists have taught the world through research. The Hib vaccine alone has saved more than 660,000
More informationGROUNDBREAKING FOCUS REVOLUTIONARY IMPACT
Cancer Research Institute One Exchange Plaza 55 Broadway, Suite 1802 New York, NY 10006 Phone: 212.688.7515 Toll Free: 800.99.CANCER www.cancerresearch.org @CancerResearch UNLEASHING THE POWER OF OUR OWN
More informationExcellence Without Exception
Excellence Without Exception The Eastman Institute for Oral Health (EIOH) at the University of Rochester is unique among academic health centers in the United States. Despite the absence of an undergraduate
More informationWHF Salim Yusuf Emerging Leaders Programme
WHF Salim Yusuf Emerging Leaders Programme Empowering the next generation of leaders to shape the future of cardiovascular health www.whfel.org Investing in the CVD leadership of the future The World Heart
More informationRemarks of Senator Hillary Rodham Clinton National Alliance for Autism Research November 19, 2003
Remarks of Senator Hillary Rodham Clinton National Alliance for Autism Research November 19, 2003 Hello everyone, it is an honor to be here today. The National Alliance for Autism Research (NAAR) has come
More informationCancer Screenings and Community Outreach Report The University of Toledo Medical Center Cancer Committee 2017
Cancer Screenings and Community Outreach Report The University of Toledo Medical Center Cancer Committee 2017 COMMUNITY OUTREACH At The Eleanor N. Dana Cancer Center at The University of Toledo, we see
More informationPhase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Find Studies About Studies Submit Studies Resources About Site Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG The safety and scientific validity of
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential
More informationGiving Opportunities Center for Regenerative Medicine $5 million
Beyond Extraordinary Giving Opportunities Name Center for Regenerative Medicine Leukemia Center of Excellence Lymphoma Center of Excellence Multiple Myeloma Center of Excellence The Infusion Treatment
More informationCLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014
CLINICAL RESEARCH IN GEORGIA UPDATE Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 Georgia CORE is a public-private partnership dedicated to generating collaborative resources for
More information"THERE ARE NO LIMITATIONS TO WHAT YOU CAN DO IF YOU HAVE THE DETERMINATION. - CHRISTOPHER REEVE
"THERE ARE NO LIMITATIONS TO WHAT YOU CAN DO IF YOU HAVE THE DETERMINATION. - CHRISTOPHER REEVE What is the NeuroRecovery Network? The NeuroRecovery Network (NRN) is a cooperative network of cuttingedge
More information2nd Annual Birthdays Ball
The American Cancer Society s 2 nd Annual Birthdays Ball promises to be the most exciting opportunity for your company to make a commitment to the health and well-being of our community. Your company s
More informationAgenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research charity. As research experts,
More informationThursday, February 6, 2014 Embassy of Italy, Washington, D.C. Sponsorship Opportunities
Thursday, February 6, 2014 Embassy of Italy, Washington, D.C. Sponsorship Opportunities Proceeds to Benefit Bella Notte An Evening to Benefit Pediatric Brain Tumor Research About the Brain Tumor Institute
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationTranslating Duke Health. Accelerating discovery and its translation
Translating Duke Health Accelerating discovery and its translation Translating Duke Health Biomedical discovery is accelerating innovative and revolutionary advancements in our understanding of human biology,
More informationCanines and Childhood Cancer. Examining the Effects of Therapy Dogs with Childhood Cancer Patients and their Families Executive Summary
Canines and Childhood Cancer Examining the Effects of Therapy Dogs with Childhood Cancer Patients and their Families Executive Summary Advances in medical knowledge, treatment and technology have all but
More information12 th Annual Run for Gus 2014 Sponsorship Packet
It s time to lace up your running shoes for the 12th Annual Run for Gus benefiting pediatric brain tumor research and support services at the Ann & Robert H. Lurie Children s Hospital of Chicago. With
More informationOnline Giving Resources Guide
Online Giving Resources Guide This booklet provides coordinators, parents and supporters with a variety of resources to help with promoting your school s Pennies for Patients program and online giving
More informationBrain Spine Tumors Children
Brain Spine Tumors Children 1 / 6 2 / 6 3 / 6 Brain Spine Tumors Children A vascular brain tumor is a benign (noncancerous) tumor that s caused by an excess growth of blood vessels in the brain or spinal
More informationPet dog with tumor pioneered treatment
Health Pet dog with tumor pioneered treatment 1 Courtesy Of Anita Ziebe Gracie's tumor was treated with a trial process that may help humans. Suzanne Leigh June 5, 2013 When Gracie, an 11-year-old Jack
More informationCANCER LEADERSHIP COUNCIL
CANCER LEADERSHIP COUNCIL A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS ADDRESSING PUBLIC POLICY ISSUES IN CANCER November 17, 2015 Andy Slavitt Acting Administrator Centers for Medicare
More informationUnited Way 2017 Campaign s
United Way 2017 Campaign Emails This document contains email messaging for your United Way of Greater St. Louis Campaign. You will find 1 pre-kickoff email, 2 kickoff emails, 4 reminder emails, and a variety
More informationTHE BENEFITS THE PARTNERS WHAT IS IMMUNOTHERAPY? HOW WILL IT WORK? WHY CANCER RESEARCH INSTITUTE? WHY ISRAEL CANCER RESEARCH FUND?
A groundbreaking, collaborative campaign bringing together the Cancer Research Institute, the leading nonprofit funder of immunotherapy research internationally, with the Israel Cancer Research Fund, North
More informationConnecting the Dots Social Media and Influence. Nancy Benavente Cedars Sinai Medical Center
Connecting the Dots Social Media and Influence Nancy Benavente Cedars Sinai Medical Center Nabenavente@gmail.com CARA 2011 1 Everything you do should at least create the beginning of a relationship 2 Relationships
More informationGenomic explorations have offered us a great deal. Buried Treasure
18 Buried Treasure Noncoding DNA makes up the majority of our genomes, much of it being conserved and transcribed. Though the functions of small regulatory RNA molecules are well known, what about so-called
More informationUC San Diego HIV Institute Creating a Future Without HIV/AIDS
UC San Diego HIV Institute Creating a Future Without HIV/AIDS Executive Summary HIV/AIDS will never cure itself, but at the University of California San Diego and UC San Diego Health, we believe that we
More informationFacts and Resources: Pediatric Cancer Survivorship
Facts and Resources: Pediatric Cancer Survivorship Overview The term "cancer survivors" refers to those people who have been diagnosed with cancer and the people in their lives who are affected by the
More informationSelumetinib (AZD6244; ARRY ) Pediatric MATCH. George Kirk June 2016
Selumetinib (AZD6244; ARRY-142886) Pediatric MATCH George Kirk June 2016 MEK activation and selumetinib MOA MEK is a fundamental component of the MAPK pathway a central oncogenic signalling pathway frequently
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationRadical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa
Radical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa Figure 1: Major blood cells that differentiate from hematopoietic stem cells. Hematopoietic stem cells differentiate into
More information2nd Annual Prostate Cancer Awareness Fundraising Dinner
2nd Annual Prostate Cancer Awareness Fundraising Dinner Host Lydia Borgatta Director and Relationship Manager in the Private Bank Credit Suisse New York Thursday, September 27, 2012 program Cocktails &
More informationVictorian Paediatric Oncology Situational Analysis & Workforce Requirements
- Victorian Paediatric Oncology Situational Analysis & Workforce Requirements 2012-2026 SUMMARY REPORT May 2013 1 Contents Executive summary...3 1. Introduction...6 2. Project method...8 2.1 Estimating
More informationMontefiore Einstein Center for Cancer Care. Pioneering Treatments. Extraordinary Possibilities.
Montefiore Einstein Center for Cancer Care Pioneering Treatments. Extraordinary Possibilities. Dear Colleague, Now is a time of extraordinary possibility in the field of cancer research and treatment.
More informationINDIANA UNIVERSITY SCHOOL OF PUBLIC HEALTH BLOOMINGTON
INDIANA UNIVERSITY SCHOOL OF PUBLIC HEALTH BLOOMINGTON OR ALL WHO NVISION A EALTHIER ORLD At the Indiana University School of Public Health Bloomington, we are building on our university s longstanding
More informationempower youth mentor
empower youth mentor Mission We foster and facilitate high quality, safe mentoring relationships for children in need. About Us Big Brothers Big Sisters of Waterloo Region (BBBSWR) is a community organization
More informationStrategic Plan for Science
Strategic Plan for Science 2018 2020 OVERVIEW Autism Speaks Mission Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the lifespan, to meet the needs of individuals
More informationThe 2015 donations will be transformative:
2015 Impact Funding Allocations Cycle for Survival is determined to beat rare cancers by powering groundbreaking research. Participants and donors fight so all patients have the treatment options they
More informationTRANSCRIPT Opening Remarks
TRANSCRIPT Opening Remarks Amy Gutmann, Ph.D. Commission Chair James Wagner, Ph.D. Commission Vice-Chair Meeting 5, Day 1 Opening Remarks May 18, 2011 New York, New York DR. GUTMANN: Good morning, everybody.
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationOur Story. About the Team Brock - Cure Starts Now Partnership
Our Story Brock Fleming was a happy, healthy and energetic 7 year old boy. He had a loving smile, caring heart and infectious laugh, the kind of kid you would never forget. In an instant, his life changed.
More informationYMCA Calgary. Strategic Plan
YMCA Calgary Strategic Plan YMCA Calgary Strategic Plan 2009 2013 In 2008, YMCA Calgary engaged its staff, Board of Directors and community partners to chart a course for the following five years. The
More information